These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3258043)

  • 1. [Clinical significance of beta-lactamase inhibitors].
    Adam D
    Klin Wochenschr; 1988 Jan; 66(2):81-3. PubMed ID: 3258043
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of beta-lactamase inhibitors in the etiotropic therapy of infectious diseases].
    Orlov VA; Sarsenbaeva DI
    Antibiot Khimioter; 1993; 38(4-5):63-70. PubMed ID: 8031200
    [No Abstract]   [Full Text] [Related]  

  • 3. Superbugs and Superdrugs: a focus on antibacterials--6th annual SMi conference.
    Georgopapadakou N
    Expert Opin Emerg Drugs; 2004 May; 9(1):191-5. PubMed ID: 15155144
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibacterial activity of an oral penem, Sch 29482.
    Neu HC; Labthavikul P
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():49-57. PubMed ID: 6977533
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and beta-lactamase inhibitory activity of 7 alpha-hydroxyethyl cephem derivatives.
    Nishimura S; Yasuda N; Sasaki H; Matsumoto Y; Kamimura T; Sakane K; Takaya T
    J Antibiot (Tokyo); 1989 Jan; 42(1):159-62. PubMed ID: 2784130
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-spectrum beta-lactamases: the role of inhibitors in therapy.
    Amyes SG; Miles RS
    J Antimicrob Chemother; 1998 Oct; 42(4):415-7. PubMed ID: 9818738
    [No Abstract]   [Full Text] [Related]  

  • 8. The carbapenem family.
    Basker MJ
    J Antimicrob Chemother; 1982 Jul; 10(1):4-7. PubMed ID: 6980875
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.
    Weiss WJ; Petersen PJ; Murphy TM; Tardio L; Yang Y; Bradford PA; Venkatesan AM; Abe T; Isoda T; Mihira A; Ushirogochi H; Takasake T; Projan S; O'Connell J; Mansour TS
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4589-96. PubMed ID: 15561830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe.
    Milatovic D; Schmitz FJ; Verhoef J; Fluit AC
    J Antimicrob Chemother; 2002 Aug; 50(2):293-9. PubMed ID: 12161416
    [No Abstract]   [Full Text] [Related]  

  • 11. Current concepts of antimicrobial therapy. I.
    Pickering LK; Murray BE
    J Trop Pediatr; 1984 Apr; 30(2):119-22. PubMed ID: 6610058
    [No Abstract]   [Full Text] [Related]  

  • 12. [Beta-lactamase inhibitors].
    Launay O; Joly-Guillou ML; Decré D; Crémieux AC
    Presse Med; 1997 Mar; 26(10):485-92. PubMed ID: 9137377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for expanding the use of beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1992 Nov; 37(5):297-8. PubMed ID: 1433250
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel method for determination of beta-lactamase using the agar dilution method.
    Tsuji H
    Chemotherapy; 1983; 29(6):401-7. PubMed ID: 6360576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations.
    Dudley MN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S23-8. PubMed ID: 7606586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical use of β-lactam-β-lactamase inhibitors.
    Chan K; Mack D; El-Mugamar H
    Infect Dis (Lond); 2016 Sep; 48(9):703-4. PubMed ID: 27207186
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibiotic synergism and antimicrobial combinations in clinical infections.
    Eliopoulos GM; Moellering RC
    Rev Infect Dis; 1982; 4(2):282-93. PubMed ID: 7051231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Broad-spectrum beta-lactamases. Clinical significance and detection methods].
    Sidorenko SV
    Antibiot Khimioter; 2001; 46(12):27-34. PubMed ID: 12108090
    [No Abstract]   [Full Text] [Related]  

  • 20. Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria.
    Leigh DA; Bradnock K; Marriner JM
    J Antimicrob Chemother; 1981 Mar; 7(3):229-36. PubMed ID: 6974165
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.